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Is Busk and Serlin’s measure of therapy effect size d a suitable 
measure for use in therapy studies? Evidence from simulations. 
Introduction 
Beeson & Robey (2006) suggest that Busk and Serlin’s (1992) d1 (henceforth dBS) is the best 
measure of effect size, and one that should be routinely reported in therapy studies and is 
suitable for use in meta-analysis of single case therapy studies.  
Our impression is that this measure is widely used and reported in single case studies  
What are the criteria for a good of effect size suitable for meta-analysis? 
We would suggest the following: 
1. The measure of effect size should be unbiased in the standard statistical sense. 
2. p values and confidence intervals can be calculated from the effect size. 
3. The effect size measure should be directly related to the amount of improvement. 
4. More rapid improvement should be directly reflected in a larger effect size. 
5. It should be sensitive to trend across a set of baseline trials.  
We investigated the properties of dBS in a large number of simulations. We were particularly 
interested in whether it was affected by autocorrelation – the tendency for performance on 
one session to be related to performance on previous sessions. There are two possible 
aspects to this. 
The first is session-level dependence; the overall probability of correct performance can vary 
depending on the level of performance in the previous session. The second, independent 
factor is item-level dependence. If an item is correct on one occasion it will be more likely to 
named correctly the next time it is presented than if it had been incorrectly named on the 
previous occasion. 
Either aspect will result in autocorrelation that is well known to threaten statistical analysis of 
time series data. 
Method 
We conducted a set of simulations of patient data varying the following factors: 
(i) auto: this is the lag 1 autocorrelation between the underlying probability correct on 
trial n and trial n+1. This was varied from 0 to 0.25, 0.5 and 0.75. auto represents 
session-level dependence. 
(ii) k: this is the odds ratio for correct performance on trial n for items correct on trial n-1 
relative to items incorrect on trial n-1. This was varied from 1 to 5, 20 and 100. 
The value of k represents item-level dependence. 
Together auto and k result in a measured degree of lag 1 autocorrelation that we 
call lag1r. 
(iii) n: this is the number of items in the test. This was varied from, 10 to 20, 50, 100. 
(iv) trials: this is the length of the baseline sequence.  This was varied from 3 to 5, 10, 15 
and 20. 
(v) intendedsd:  this is the target sd for the sd of the underlying probability correct. It 
represents the degree of session-to-session variability related to session-level 
dependence. This was varied from 0.10 to 0.05, 0.025 and 0.01. The obtained sd 
was necessarily different and is called σr . 
In addition the model was run with auto=0 and intendedsd=0, varying  k, n and trials as 
before. 
In each case we generated a sequence of 10020 trials. We defined the true dBS as (0.90-
mean baseline)/sd baseline. (The 0.9 is arbitrary and unimportant). We compared the 
measured dBS in each simulation from n items over trials trials. Across the 1360 
combinations of conditions, each involving 10000 simulations, we could investigate, using 
simultaneous multiple regression how sample estimates of dBS are related to true dBS and 
how dBS estimates are affected by n, trials (t), logk, σr, lag1r  and auto. 
Results 
On average 0.9% of runs had no variation in the sampled baseline (with a range from 0 to 
25.6%) resulting in dBS of infinity. These runs are eliminated in the results that follow. 
In every one of the 1360 simulations the mean dBS was significantly greater than the true dBS  
(t test p<.001; see Figure 1). 
The overestimation varies from 2.3% to 211% with a mean of 41.3%. Recall that mean dBS, 
is always calculated over 10000 observations; individual values of dBS will, of course, be 
much more variable. 
In every case (of the 1360 simulations), mean dBS is significantly greater than the true dBS. 
Clearly, it is a biased estimator of the true dBS effect size. 
The determinants of overestimation of true dBS.   
We investigated how the degree of overestimation (defined as mean dBS/true dBS) was 
related to n, auto, logk, t, σr, and lag1r using simultaneous multiple regression. 
The degree of overestimation was related to t (t(1353)=48.70, p<.001, η2 = 0.64), lag1r 
(t(1353)=12.06, p<.001, η2 = 0.097), n (t(1353)=5.16, p<.001, η2 = 0.019) and logk (t(1353)= 
3.78, p<.001, η2 = 0.010), but not auto (t(1353)=1.62, p=.11, η2 = 0.002), or σr (t(1353)=0.97, 
p=.33, η2 = 0.001). 
Figure 1. The relationship between mean dBS and true dBS. The dotted line is represents equal values 














Overestimation is always present but it is greater when there are fewer trials in the baseline, 
when there is greater autocorrelation of the scores on successive trials, when there are more 
items in the test and when item-level consistency is greater. 
The two determinants with most influence on the degree of overestimation are the number of 
trials in the baseline, t, and the lag 1 autocorrelation, lag1r. The effects of these variables are 
illustrated in Figure 2. The graph makes it clear again that measured dBS always 
overestimates the true dBS; this is true even where there is no lag 1 autocorrelation. The 


























Figure 2. The relationship between mean overestimation of dBS, the number of trials in the 



































So, as a result of these simulations, what do we know about how dBS behaves in relation to 
the criteria we advanced in the introduction? 
(i) dBS is a biased measure. 
In the simulations, dBS is widely variable but its mean is, in every case, greater than 
the true value. The degree to which it overestimates the true dBS is primarily related 
to two factors: it is greater with fewer trials in the baseline and with more 
autocorrelation in the baseline series (other factors have significant, though 
substantially smaller, effects on mean dBS). 
(ii) The effect size has a direct interpretation. 
It is clear that dBS varies with a number of factors, but it is not clear how its value is to 
be interpreted.   
(iii) p values and confidence intervals can be calculated from the effect size. 
We know of no way that p values (and hence confidence intervals) can be calculated 
from dBS. The result is that readers cannot easily discriminate between therapy effect 
sizes that might easily have occurred by chance and those that are a result of real 
improvement.  
(iv) The effect size measure should be directly related to the amount of improvement. 
In data not presented here we show that the absolute amount of improvement and 
dBS is not linear. 
(v) More rapid improvement should be directly reflected in a larger effect size. 
dBS as a measure takes no account of the number of sessions in therapy. As a result, 
it is clearly unable to capture anything about the rate of improvement. 
(vi) It should be sensitive to trend across a set of baseline trials.  
dBS takes no account of any trend across the baseline trials.  
To summarise, dBS as a measure of effect size does not meet any of the criteria we 
suggested as necessary for an effect size measure suitable for meta-analysis that we 
think are uncontroversial. 
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